In the xenograft assay, the Lv‐MEF2A group exhibited reduced tumour size (Figure 8A), weight (Figure 8B) and volume (Figure 8C) compared to the vector group, indicating that MEF2A can inhibit tumour growth in RCC. Here, MEF2A is linked to renal cell carcinoma.